Download MendeleyStructure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.
Kim, S.H., Tran, M.T., Ruebsam, F., Xiang, A.X., Ayida, B., McGuire, H., Ellis, D., Blazel, J., Tran, C.V., Murphy, D.E., Webber, S.E., Zhou, Y., Shah, A.M., Tsan, M., Showalter, R.E., Patel, R., Gobbi, A., LeBrun, L.A., Bartkowski, D.M., Nolan, T.G., Norris, D.A., Sergeeva, M.V., Kirkovsky, L., Zhao, Q., Han, Q., Kissinger, C.R.(2008) Bioorg Med Chem Lett 18: 4181-4185
- PubMed: 18554907
- DOI: https://doi.org/10.1016/j.bmcl.2008.05.083
- Primary Citation of Related Structures:
3D28, 3D5M - PubMed Abstract:
A novel series of HCV NS5B polymerase inhibitors comprising 1,1-dioxoisothiazoles and benzo[b]thiophene-1,1-dioxides were designed, synthesized, and evaluated. SAR studies guided by structure-based design led to the identification of a number of potent NS5B inhibitors with nanomolar IC(50) values. The most potent compound exhibited IC(50) less than 10nM against the genotype 1b HCV polymerase and EC(50) of 70 nM against a genotype 1b replicon in cell culture. The DMPK properties of selected compounds were also evaluated.
Organizational Affiliation:
Anadys Pharmaceuticals, Inc., 3115 Merryfield Row, San Diego, CA 92121, USA. sdsunhee@yahoo.com
